Vertex Pharms patents expiration
1. Incivek patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7820671 | VERTEX PHARMS | Peptidomimetic protease inhibitors |
Feb, 2025
(10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8529882 | VERTEX PHARMS | Peptidomimetic protease inhibitors |
Aug, 2021
(2 years ago) | |
| US8431615 | VERTEX PHARMS | Dose forms |
May, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 23, 2016 |
Drugs and Companies using TELAPREVIR ingredient
NCE-1 date: 24 May, 2015
Market Authorisation Date: 23 May, 2011
Treatment: Method of treating chronic hepatitis c
Dosage: TABLET;ORAL
INCIVEK family patents
2. Kalydeco patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8754224 | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| US7495103 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
May, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8629162 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Jun, 2025
(1 year, 1 month from now) | |
| US8354427 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Jul, 2026
(2 years from now) | |
| US8410274 | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| US9670163 | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| US8324242 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Aug, 2027
(3 years from now) | |
| US10646481 | VERTEX PHARMS | Pharmaceutical composition and administrations thereof |
Aug, 2029
(5 years from now) | |
| US11564916 | VERTEX PHARMS | Pharmaceutical composition and administrations thereof |
Aug, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-189) | Jul 31, 2024 |
| Orphan Drug Exclusivity(ODE-190) | May 17, 2024 |
| Orphan Drug Exclusivity(ODE-199) | Aug 15, 2025 |
| Orphan Drug Exclusivity(ODE-338) | Dec 21, 2027 |
| New Indication(I-705) | Dec 30, 2017 |
| Orphan Drug Exclusivity(ODE-187) | Dec 29, 2021 |
| Orphan Drug Exclusivity(ODE-186) | Feb 21, 2021 |
| New Indication(I-740) | Feb 21, 2017 |
| New Patient Population(NPP) | Jul 31, 2020 |
| Orphan Drug Exclusivity(ODE-20) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2017 |
Drugs and Companies using IVACAFTOR ingredient
NCE-1 date: 01 February, 2016
Market Authorisation Date: 20 May, 2019
Treatment: Use of ivacaftor for treating cystic fibrosis in a patient with a mild to moderate cf phenotype with at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in ...
Dosage: TABLET;ORAL
KALYDECO family patents